What adjuvant therapy would you offer a TNBC patient with residual disease after receiving the neoadjuvant KEYNOTE-522 regimen?
Community PollStarted
What adjuvant therapy would you use for TNBC with residual disease after neoadjuvant KN-522 regimen?
67 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Cedars-Sinai Medical Center
Answered on
Safety is pembro and cape was provided in phase I trials. Risk and benefit weighing is important when discussing with patients.
Join for free or sign in to see the full answer